Partnership story

Archived content.

Collaboration between TB Alliance and Tibotec offers hope of accelerated tuberculosis drug development


In response to the urgent need to accelerate the discovery and development of new drugs to fight tuberculosis (TB), a landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a non-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, was announced at the Pacific Health Summit.

The two organisations have agreed to share their expertise and resources in the development of “TMC207”, an anti-tuberculosis drug with a new mechanism of action.

The interim data from an ongoing Phase II study of TMC207 were recently published in the New England Journal of Medicine. In the placebo-controlled study of 47 patients with multidrug-resistant TB (MDR-TB), it was found that 48% of patients receiving TMC207 in combination with standard treatment converted to negative sputum culture after eight weeks compared with 9% of those who received placebo and standard treatment.

TB is among the leading causes of death among people living with HIV, and accounts for an estimated 23% of AIDS deaths worldwide.